For much of the past five years, the cannabis industry has been defined by disappointment. Public equities are down approximately
The European medical cannabis industry is continuing to mature, seeing companies focused on science-based research push the boundaries of our
Amid rising global scrutiny of the wider medical cannabis prescription model, and with markets like France leaning into pharmaceutical-grade regulation, the pharma cannabis sector is shaping up to be one of the most dynamic and closely watched corners of the industry.
Welcome to Business of Cannabis’ new weekly strategic digest tracking the financial health, market moves, and corporate developments shaping the European cannabis sector.
Argent BioPharma [stock_market_widget type=”chart” template=”line” assets=”RGT.AX” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Argent BioPharma has
Ananda Pharma, now the leading force in pharmaceutical cannabis research in the UK, has announced that the former Chief Operating
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.
British American Tobacco [stock_market_widget type=”chart” template=”line” assets=”BATS.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Tobacco giant
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”line” assets=”JAZZ” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The pharmaceutical giant
As reported by Cannabis Health Avata Biosciences is developing solid dose cannabinoid medicines for epilepsy and other neurological disorders, with
Germany’s passage of CanG continues to drive up stock prices Yesterday, the President of Bundesrat, Manuela Schwesig, signed Germany’s landmark
IM Cannabis IM Cannabis has become the latest major Israeli cannabis company to announce potential plans to depart the industry
Jazz Pharmaceuticals has rebuffed attempts by rival Teva Pharmaceuticals to legally disqualify its patent for Epidyolex, a cannabis-based drug worth
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”JAZZ” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Epidiolex (Epidyolex in the EU
Japan, one of the world’s strictest and most hostile countries in regard to cannabis, recently took a major step towards
Big pharma has so far been cautious of diving headfirst into the cannabis industry, despite the growing body of evidence
German Stocks Spike on Passage of Draft Law [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”SBX.DE” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”]
We won’t spam you
